On April 2, 2026, the ECCK Healthcare Committee invited Mr Kangseop Lim, Director of the Pharmaceutical and Bio Industry Division at the Ministry of Health and Welfare (MoHW), to a roundtable meeting.
The Pharmaceutical and Bio Industry Division has been newly established to further support the development of the industry under its updated mandate. During the session, Director Lim introduced the recent revision proposal concerning the designation of Innovative Pharmaceutical Companies, along with the proposed timeline. ECCK committee members engaged in an in-depth discussion on the proposal, sharing their perspectives and industry insights.
The ECCK would like to express its sincere appreciation to Director Lim for providing this valuable opportunity for dialogue with the industry, as well as to all participants for their constructive contributions. The ECCK looks forward to continued cooperation with the MoHW.
ECCK Healthcare Committee Engages MoHW on Revised Innovative Pharma Designation Framework
On April 2, 2026, the ECCK Healthcare Committee invited Mr Kangseop Lim, Director of the Pharmaceutical and Bio Industry Division at the Ministry of Health and Welfare (MoHW), to a roundtable meeting.
The Pharmaceutical and Bio Industry Division has been newly established to further support the development of the industry under its updated mandate. During the session, Director Lim introduced the recent revision proposal concerning the designation of Innovative Pharmaceutical Companies, along with the proposed timeline. ECCK committee members engaged in an in-depth discussion on the proposal, sharing their perspectives and industry insights.
The ECCK would like to express its sincere appreciation to Director Lim for providing this valuable opportunity for dialogue with the industry, as well as to all participants for their constructive contributions. The ECCK looks forward to continued cooperation with the MoHW.